+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Self-injection Devices Market Size, Share & Trends Analysis Report by Product (Autoinjectors, Needle-free Injectors), by Usability (Disposable, Reusable), by Application (Cancer, Pain Management), by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 120 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 5595832
The global self-injection devices market size is expected to reach USD 10.8 billion by 2030. It is projected to expand at a CAGR of 5.7% from 2022 to 2030. Increasing patient volume and rising prevalence of chronic diseases along with the high adoption of advanced drug delivery systems are factors estimated to surge the demand for self-injection devices.



Prevention of needlestick injury is a primary factor for healthcare professionals and companies to introduce self-injection devices such as autoinjectors. To avoid needlestick injuries to healthcare workers, the U.S., Europe, and other markets mandate the use of safety devices. Several auto-injectors provide the additional benefit of needlestick protection to healthcare professionals. It is expected that in the U.S. about 69,000 injuries can be prevented annually. Numerous auto-injectors have integral and passive safety features that eliminate or reduce the risk of injury.

Innovation in the field of New Drug Delivery Systems (NDDDS) has led to the rising demand for self-administered medications. The invention of novel injectable delivery devices such as pre-filled syringes, pen injectors, autoinjectors, and needle-free injectors has made the self-administration of drugs easier and more convenient for patients. The majority of biological drugs are delivered using injections, which include the threat of needlestick injuries. To minimize this issue, pharmaceutical firms are developing self-administered needle-free injectors and patient-friendly medication-device combination products.

The COVID-19 pandemic has altered expectations and perceptions of delivery settings and contributed to a rise in preference for self-administration medication. As this becomes the norm, several manufacturers are inclined to make the patient experience the vital component of drug delivery design. Significantly, the COVID-19 vaccines will increase the demand for injectable devices and the pandemic has also shown the benefit of self-use devices as well as connected devices. Post-pandemic there may be a rise in upcoming innovation in devices and pharma manufacturers will progressively collaborate to use self-injection devices in combination with other digital assets such as apps, phones, and personal computers. Eventually, this will bring the patient into far greater control of their care.

Self-injection Devices Market Report Highlights

  • Needle-free injectors segment held the largest market share in 2021 owing to the rising demand for needle-free injectors and increased health consciousness among individuals.
  • The disposable segment held a significant market share in 2021 due to the ease of use and the presence of a built-in glass syringe that reduces the necessity of manually loading the glass syringe, eventually making it more convenient for patients.
  • The cancer segment is anticipated to gain the highest market share during the forecast period due to the increasing prevalence of cancer all across the globe.
  • North America led the market in 2021 owing to the increasing demand for self-injection devices used for the treatment of several chronic diseases.
  • The Asia Pacific region is expected to expand at the fastest CAGR during the forecast period due to the rising incidence of autoimmune diseases and high prevalence of cancer across several countries in the region.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Usability
1.1.3. Application
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Usability outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Self-injection Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of chronic disorders
3.4.1.2. Technological advancements
3.4.1.3. Increasing cases of
3.4.2. Market restraint analysis
3.4.2.1. Lack of awareness in developing and underdeveloped economies
3.4.2.2. Stringent regulations
3.5. Self-injection Devices Market Analysis Tools
3.5.1. Industry Analysis-Porter’s
3.5.1.1. Supplier product
3.5.1.2. Buyer product
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Self-injection Devices: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Autoinjectors
4.1.2. Pen Injectors
4.1.3. Wearable Injectors
4.1.4. Needle-free Injectors
4.2. Product Market Share, 2021 & 2030
4.3. Segment Dashboard
4.4. Global Self-injection Devices Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
4.5.1. Autoinjectors
4.5.1.1. Market estimates and forecast 2017 to 2030 (USD Million)
4.5.2. Pen Injectors
4.5.2.1. Market estimates and forecast 2017 to 2030 (USD Million)
4.5.3. Wearable Injectors
4.5.3.1. Market estimates and forecast 2017 to 2030 (USD Million)
4.5.4. Needle-free injectors
4.5.4.1. Market estimates and forecast 2017 to 2030 (USD Million)
Chapter 5. Self-injection Devices: Usability Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Disposable
5.1.2. Reusable
5.2. Usability Market Share, 2021 & 2030
5.3. Segment Dashboard
5.4. Global Self-Injection Devices Market by Usability Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
5.5.1. Disposable
5.5.1.1. Market estimates and forecast 2017 to 2030 (USD million)
5.5.2. Reusable
5.5.2.1. Market estimates and forecast 2017 to 2030 (USD Million)
Chapter 6. Self-injection Devices: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Cancer
6.1.2. Autoimmune Disorders
6.1.3. Hormonal Disorders
6.1.4. Pain Management
6.1.5. Others
6.2. Application Market Share, 2021 & 2030
6.3. Segment Dashboard
6.4. Global Self-injection Devices Market by Application Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
6.5.1. Cancer
6.5.1.1. Market estimates and forecast 2017 to 2030 (USD million)
6.5.2. Autoimmune Disorders
6.5.2.1. Market estimates and forecast 2017 to 2030 (USD Million)
6.5.3. Hormonal Disorders
6.5.3.1. Market estimates and forecast 2017 to 2030 (USD Million)
6.5.4. Pain Management
6.5.4.1. Market estimates and forecast 2017 to 2030 (USD Million)
6.5.5. Others
6.5.5.1. Market estimates and forecast 2017 to 2030 (USD Million)
Chapter 7. Self-injection Devices Market: Regional Estimates & Trend Analysis
7.1. Regional market share analysis, 2021 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Regional Market Share and Leading Players, 2020
7.4.1. North America
7.4.2. Europe
7.4.3. Asia Pacific
7.4.4. Latin America
7.4.5. Middle East and Africa
7.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East and Africa
7.6. Market Size, & Forecasts, Volume and Trend Analysis, 2017 to 2030:
7.7. North America
7.7.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.7.2. U.S.
7.7.2.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.7.3. Canada
7.7.3.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.8. Europe
7.8.1. U.K.
7.8.1.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.8.2. Germany
7.8.2.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.8.3. France
7.8.3.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.8.4. Italy
7.8.4.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.8.5. Spain
7.8.5.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.9. Asia Pacific
7.9.1. China
7.9.1.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.9.2. Japan
7.9.2.1. Market estimates and forecast, 2017-2030 (Volume, Thousand)
7.9.3. India
7.9.3.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.9.4. South Korea
7.9.4.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.9.5. Australia
7.9.5.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.10. Latin America
7.10.1. Brazil
7.10.1.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.10.2. Mexico
7.10.2.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.10.3. Argentina
7.10.3.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.10.4. Colombia
7.10.4.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.11. MEA
7.11.1. Saudi Arabia
7.11.1.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.11.2. South Africa
7.11.2.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
7.11.3. UAE
7.11.3.1. Market estimates and forecast, 2017-2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2021
8.3.4. Ypsomed AG.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. BD
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Gerresheimer AG
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Antares Pharma
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Haselmeier AG
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. NuGen Medical Devices
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Owen Mumford Ltd.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. SHL Medical AG
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Pfizer, Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Amgen
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives

Companies Mentioned

  • Ypsomed Ag.
  • Bd
  • Gerresheimer AG
  • Antares Pharma
  • Haselmeier AG
  • Nugen Medical Devices
  • Owen Mumford Ltd.
  • Shl Medical AG
  • Pfizer, Inc.
  • Amgen

Methodology

Loading
LOADING...

Table Information